Blastolysin - hepaton - promolan is a traditional remedy to treat and prevent chorioepithelioma especially in mild and moderate cases. This remedy has been proved to apply in benign prostatic hyperplasia. Evaluation after treatment by taking drug continuously in three months: Obstacle and irritable symptoms reduce in almost patients. Volume of prostate in echography image became significantly smaller. Initial results: very good 9 cases (19.1%), good 19 cases (40.4%), moderate is 16 cases (34.0%), poor 3 cases (6.3%). This remedy is not poisonous is widely indicated and suitable for many kind of patients such as elder patients, suffering from many diseases, no indication or unwillingness for operation... It costs less than ongoing therapy. As being hypertrophy prostate is current subject, many doctors and even patients concerned with, blastolysin therapy should be studied further.
Prostatic Hyperplasia ; therapy

From 6/1981 to 6/1996 a total of 978 consecutive patients (mean age: 69) presenting with bladder outlet obstructive were admitted to Viet Duc hospital for elective transurethral resection of prostate). The feagure of TURP were increasing from year to year and the TURP/ open surgery ratio was 80% in 1996. The procedures were performed with low mortality (0.3%) and low morbidity (bleeding 0.6%, capsular perforation (0.7%). TURP syndrome (0.3%), dysuria (1.8%) incontinence (1.1%), urethral stricture (1.5%) Hospital stay: 5(2 days. Overall outcome: good: 77%, moderate 19%; unsatis factory: 4%.
Prostatic Hyperplasia ; therapy ; surgery

Transurethral electrovaporisation of prostate (TVP or TUVP) is a new modification of transurethral resection of prostate (TURP). The goal of TVP in benign prostatic hyperplasia (BHP) is reduce the incidence of TURP complications. From 1996 to June 1997, the first time 12 patients have been indicated TVP for BHP in Cho Ray Hospital. The participants included those who have been not operated and those who have been operated using TURP previously. Several kinds of electrodes were used. The roller type was better but it makes the time of TVP longer. The sharp type is easier to cause complications. Perforation of capsule occurred in one patient.
Prostatic Hyperplasia ; therapy

Humans ; Laser Therapy ; Male ; Prostatic Hyperplasia ; surgery

Disease Progression ; Humans ; Male ; Prostatic Hyperplasia ; therapy ; Transurethral Resection of Prostate

China ; Humans ; Laser Therapy ; Male ; Prostatic Hyperplasia ; surgery

PURPOSE: The aim of this study was to evaluate the efficacy of a combination drug therapy (tamsulosin plus finasteride) for benign prostatic hyperplasia, with a small prostate volume of less than 40 grams. MATERIALS AND METHODS: One hundred and twenty-three patients, with symptomatic benign prostatic hyperplasia of less than 40 grams, were analysed. Group 1 (n=67) had been treated with a combination of finasteride (5mg/day) and tamsulosin (0.2mg/ day), and Group 2 (n=56) with tamsulosin only (0.2mg/day) over a 12 month period. The patients were periodically assessed by IPSS (international prostate symptom score), uroflowmetry and residual urine, during the treatment period. RESULTS: The mean changes in the total symptom score, obstructive and irritative symptom score for group 1 and group 2 at 1 year were -7.21+/-7.44 (39.86%), -4.79+/-5.07 (45.02%) and -2.42+/-3.25 (48.11%), and -7.39+/-9.98 (43.06%), -4.82+/-6.91 (45.21%) and -2.39+/-4.00 (37.82%) points, respectively. The mean changes in the peak urinary-flow rates and postvoid residual urine for group 1 and group 2 at 1 year were 2.07+/-5.42 (16.65%)ml/s and -31.58+/-60.99 (56.47%)ml, and 2.38+/-6.57 (16.53%)ml/s and -34.78+/-86.77 (50.24%)ml, respectively. The effects of the combination of finasteride and tamsulosin were no greater than the tamsulosin monotherapy (p>0.01). CONCLUSIONS: A combination of finasteride and tamsulosin is no more effective than tamsulosin alone, in patients with benign prostatic hyperplasia, with a prostate volume of less than 40 grams.
Drug Therapy, Combination ; Finasteride* ; Humans ; Prostate* ; Prostatic Hyperplasia*

Humans ; Male ; Practice Guidelines as Topic ; Prostatic Hyperplasia ; diagnosis ; therapy

Prostatic diseases and erectile dysfunction (ED) are common diseases in urology and andrology. Basic and clinical studies have proved that there is a close relationship between the two. This article reviews the mechanism, diagnosis and treatment of ED caused by several prostatic diseases, such as acute prostatitis, chronic prostatitis, benign prostate hyperplasia and prostate cancer.
Chronic Disease ; Erectile Dysfunction ; diagnosis ; etiology ; therapy ; Humans ; Male ; Prostatic Diseases ; complications ; Prostatic Hyperplasia ; complications ; Prostatic Neoplasms ; complications ; Prostatitis ; complications

OBJECTIVETo compare the difference in the clinical efficacy on benign prostatic hyperplasia (BPH) between the acupuncture-moxibustion therapy and the medication of Qianliekang tablets.

METHODSOne hundred and twenty-eight patients were randomized into an acupuncture-moxibustion group and a Qianliekang group, 64 cases in each one. In the acupuncture-moxibustion group, acupuncture was applied to Shenshu (BL 23), Pangguangshu (BL 28), Zhongji (CV 3), Guanyuan (CV 4) and Shuidao (ST 28), and the warm moxibustion therapy with moxa stick was used at Shenshu (BL 23), Guanyuan (CV 4) and Shenque (CV 8), once every day. In the Qianliekang group, Qianliekang tablets were prescribed for oral administration, 4 tablets each time, three times a day, for 3 months. The International Prostate Symptom Score (I-PSS) and the changes in residual urine (Ru) and maximal urine flow rate (Qmax) determined with the ultrasonic B test were compared before and after treatment in the two groups.

RESULTSThe results of I-PSS, Qmax and Ru were improved obviously after treatment as compared with those before treatment in the two groups (all P < 0.05). The improvements in the acupuncture-moxibustion group were much more obvious than those in the Qianliekang group [8.62 +/- 2.18 vs 15.26 +/- 2.81, (16.04 +/- 4.33) mL/s vs (12.47 +/- 2.13) mL/s, (10.43 +/- 2.14) mL vs (32.13 +/- 3.24) mL, all P < 0.01]. The total effective rate was 89.1% (57/64) in the acupuncture-moxibustion group, which was better than 68.7% (44/64) in the Qianliekang group.

CONCLUSIONAcupuncture-moxibustion therapy achieves the significant efficacy on BPH, which is better than the oral administration of Qianliekang tablets.

Acupuncture Therapy ; Aged ; Humans ; Male ; Middle Aged ; Moxibustion ; Prostatic Hyperplasia ; physiopathology ; therapy ; Treatment Outcome ; Urination